As of December 29, 2017, Glory Biotech Co., Ltd. was acquired by glac Biotech Co., Ltd. Glory Biotech Co., Ltd., a biotechnology company, engages in the development and production of active pharmaceutical ingredients (APIs), probiotics, health food ingredients, and animal feed ingredients in Taiwan. Its general API products include MPA intermediate and Daptomycin; and under development API products comprise Doxorubicin, Epothilone B, Rapamycin intermediate, CMS, and GLP-1. The company’s probiotics include lactobacillus sporogenes, enterococcus faecalis, streptococcus thermophiles, and bacillus subtilis; and health food products comprise mushroom drinks, antrodia, ganoderma lucidum, and enzymes. In addition, it offers functional and composite probiotic powder products, as well as provides agricultural biological agents that combine the functions of pesticide and fertilizer. In addition, it provides contract research services, such as strain improvement, fermentation process optimization and scale up, and recovery and purification process, as well as develops Synbiotics application; and items of OEM/ODM, including probiotics, genetically engineered microbes, bacillus subtilis, yeast, fungus, and enzymes, as well as API products. Glory Biotech Co., Ltd. was founded in 2000 and is based in Chiayi City, Taiwan.